Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
| 12.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rth by specific reference in such filing. Item 5.02. Departure of Directors or Certain Officers; Election of Directors |
| 07.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ¨ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 23.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | CYPHERPUNK TECHNOLOGIES INC. |
|---|---|
| Ticker | CYPH |
| CIK | 0001509745 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 47,8 Mio. USD |
| Beta | -0,22 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 4,822,000 | 0.07 | 163,182,000 | 153,506,000 | |
| 2025-09-30 | 10-Q | -3,303,000 | -0.08 | 11,399,000 | 2,695,000 | |
| 2025-06-30 | 10-Q | -16,643,000 | -0.40 | 20,042,000 | 5,717,000 | |
| 2025-03-31 | 10-Q | -15,435,000 | -0.37 | 34,879,000 | 20,840,000 | |
| 2024-12-31 | 10-K | -67,555,000 | -1.81 | 49,124,000 | 35,048,000 | |
| 2024-09-30 | 10-Q | -18,176,000 | -0.44 | 65,047,000 | 48,954,000 | |
| 2024-06-30 | 10-Q | -20,128,000 | -0.52 | 81,426,000 | 65,788,000 | |
| 2024-03-31 | 10-Q | -13,820,000 | -0.51 | 57,963,000 | 47,372,000 | |
| 2023-12-31 | 10-K | -81,414,000 | -3.98 | 72,825,000 | 60,141,000 | |
| 2023-09-30 | 10-Q | -13,696,000 | -0.51 | 83,046,000 | 72,008,000 | |
| 2023-06-30 | 10-Q | -13,390,000 | -0.91 | 95,857,000 | 84,057,000 | |
| 2023-03-31 | 10-Q | -41,863,000 | -3.24 | 106,547,000 | 28,329,000 | |
| 2022-12-31 | 10-K | -54,596,000 | -4.82 | 70,353,000 | 58,866,000 | |
| 2022-09-30 | 10-Q | -15,094,000 | -1.33 | 82,165,000 | 70,073,000 | |
| 2022-06-30 | 10-Q | -17,024,000 | -1.50 | 94,203,000 | 83,318,000 | |
| 2022-03-31 | 10-Q | -10,376,000 | -0.09 | 105,901,000 | 98,557,000 | |
| 2021-12-31 | 10-K | 1,500,000 | -40,587,000 | -0.47 | 117,911,000 | 107,887,000 |
| 2021-09-30 | 10-Q | 375,000 | -11,139,000 | -0.14 | 128,080,000 | 116,819,000 |
| 2021-06-30 | 10-Q | 375,000 | -9,526,000 | -0.12 | 37,940,000 | 29,884,000 |
| 2021-03-31 | 10-Q | 375,000 | -9,134,000 | -0.12 | 45,807,000 | 38,379,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | CAVANAUGH JAMES H | Director | Open Market Sale | -261,840 | 3.14 | -822,177.60 | -81,1% | |
| 2025-11-17 | ONSI DOUGLAS E | Director, Officer, CEO,CFO,Pres.,GC,Treas.&Sec. | Open Market Sale | -261,840 | 3.14 | -822,177.60 | -81,1% | |
| 2025-11-17 | ONSI DOUGLAS E | Director, Officer, CEO,CFO,Pres.,GC,Treas.&Sec. | Open Market Sale | -414,479 | 3.14 | -1,301,464.06 | -128,4% | |
| 2025-11-17 | Mirabelli Christopher | Director | Open Market Sale | -261,840 | 3.14 | -822,177.60 | -81,1% | |
| 2025-11-17 | Mirabelli Christopher | Director | Open Market Sale | -414,479 | 3.14 | -1,301,464.06 | -128,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.